WallStSmart

Cyclerion Therapeutics Inc (CYCN)vsRevolution Medicines Inc (RVMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Cyclerion Therapeutics Inc generates 169% more annual revenue ($1.99M vs $742,000). RVMD leads profitability with a 0.0% profit margin vs -264.7%. RVMD earns a higher WallStSmart Score of 24/100 (F).

CYCN

Avoid

21

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 4.5
Piotroski: 1/9

RVMD

Avoid

24

out of 100

Grade: F

Growth: 3.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 1/9Altman Z: -0.99
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CYCNUndervalued (+70.6%)

Margin of Safety

+70.6%

Fair Value

$4.15

Current Price

$2.98

$1.17 discount

UndervaluedFair: $4.15Overvalued

Intrinsic value data unavailable for RVMD.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

CYCN1 strengths · Avg: 8.0/10
Price/BookValuation
1.9x8/10

Reasonable price relative to book value

RVMD1 strengths · Avg: 9.0/10
Debt/EquityHealth
0.109/10

Conservative balance sheet, low leverage

Areas to Watch

CYCN4 concerns · Avg: 3.0/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$12.90M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Return on EquityProfitability
-77.7%2/10

ROE of -77.7% — below average capital efficiency

RVMD4 concerns · Avg: 3.3/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Operating MarginProfitability
0.0%3/10

Operating margin of 0.0%

Piotroski F-ScoreQuality
1/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : CYCN

The strongest argument for CYCN centers on Price/Book.

Bull Case : RVMD

The strongest argument for RVMD centers on Debt/Equity.

Bear Case : CYCN

The primary concerns for CYCN are EPS Growth, Market Cap, Piotroski F-Score.

Bear Case : RVMD

The primary concerns for RVMD are EPS Growth, Profit Margin, Operating Margin.

Key Dynamics to Monitor

CYCN profiles as a turnaround stock while RVMD is a value play — different risk/reward profiles.

CYCN carries more volatility with a beta of 1.77 — expect wider price swings.

CYCN is growing revenue faster at -43.2% — sustainability is the question.

CYCN generates stronger free cash flow (-1M), providing more financial flexibility.

Bottom Line

RVMD scores higher overall (24/100 vs 21/100). CYCN offers better value entry with a 70.6% margin of safety. Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cyclerion Therapeutics Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery, development, and commercialization of drugs for serious diseases of the central nervous system (CNS). The company is headquartered in Cambridge, Massachusetts.

Revolution Medicines Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is headquartered in Redwood City, California.

Want to dig deeper into these stocks?